alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 2,501–2,525 of 3,123 studies · tagged Treatments (page 101 of 125) · 28,580 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 14,058 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The “American (cancer) patients first” plan to reduce drug prices—A critical assessment

✓ Peer-reviewed alzhub usefulness score 36 out of 100. American Journal of Hematology 2018-09-16

Serious concerns over the rising cost of cancer drugs in the United States1-3 are increasing,4-9 following a decade during which prices rose from an average of less than $10 000/year to more than $170 000/year in 2017.10 Despite the drug industry's wish to be “part of the solution,” the problem continues to worsen.6 Between 1995 and 2013, the launch price of cancer drugs increased by 10%-12% every year.11 According to a March 2018 report, the Average Wholesale Prices of drugs increased at unprecedented rates.12 A study by Gordon and colleagues showed a 25% average annual price increase of drugs already on the market, despite competition.13 Cancer drugs spending doubled since 2013 and is expected to double again by 2022.14 This suggests that health care is different from other industries where traditional free market forces are effective in lowering prices, and that other measures are needed. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disparities in High-Risk Medication Use—Implications for Health Equity and Deprescribing Practices

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Network Open 2025-04-14

Potentially inappropriate medication (PIM) use-defined as the use of high-risk medications that can increase the risk of adverse events such as physical, cognitive, and functional decline; delirium; hospitalizations; and mortality-remains a significant concern in older adults in the US.Numerous guidelines, including the American Geriatrics Society Beers Criteria 1 and the STOPP criteria, 2 define PIMs as medications for which the risk of adverse effects outweighs potential benefits or are inappropriate for specific populations or disease states, such dementia or kidney disease.PIM use may be particularly harmful in populations experiencing other health care disparities, as communities experiencing other consequences of health care inequity, including limited access to physicians or pharmacies, greater financial stress, and a higher comorbidity burden, may experience disproportionate effects from the adverse consequences of PIM use. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

P3‐429: Response to cholinesterase inhibitor medication at first renewal in a Canadian provincial drug coverage initiative: the British Columbia Alzheimer's Drug Therapy Initiative (BC ADTI) experience

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2010-07-01

Uncertainty surrounds cholinesterase inhibitor (ChEIs) effectiveness in mild to moderate Alzheimer Disease (AD). 2 key findings →

Participants: 2,678 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Modeling Early Detection and Geographic Variation in Health System Capacity for Alzheimer’s Disease‐Modifying Therapies

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2024-12-01

Widespread delivery of AD‐modifying therapies will require a combination of strategies to communicate the value of detection and treatment to patients, integrate PCPs into the detection and diagnosis pathway, and address capacity disparities across the United States. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR ‐ SB Utilizing Semi‐Mechanistic Model

✓ Peer-reviewed alzhub usefulness score 36 out of 100. CPT Pharmacometrics & Systems Pharmacology 2026-01-16

Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to protofibrils of amyloid-beta (Aβ) protein. 5 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain PET in the era of anti-amyloid-β antibody therapy for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Japanese Journal of Radiology 2026-04-25

Here the current and emerging roles of brain positron emission tomography (PET) in Alzheimer's disease (AD) in the era of anti-amyloid-β antibody therapy, with a focus on clinical applications, methodological considerations, and future perspectives were reviewed. 5 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopes

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01

Within the limitations of measuring in vitro equilibrium binding activity of in‐house recombinant antibodies to aqueously extracted Aβ from human postmortem brain tissue, we could not discern a population of Aβ aggregates ( e.g . protofibrils) accessible to one antibody but not the other two. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s Research & Therapy 2025-04-11

The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June 2023. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab Binds to Transgenic Mouse Model‐Derived Amyloid‐β Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuropathology and Applied Neurobiology 2025-06-01

Our results show that lecanemab exhibits high binding affinity to amyloid-β fibril structures that have a flexible N-terminus in common, as is the case for type I, type II and murine type III amyloid-β fibril polymorphs, which resemble or are identical to human structures observed in sporadic and familial cases of Alzheimer's disease, including a case with the Arctic (E22G) mutation. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-04-23

Lecanemab reduced clinical decline by roughly 27% over placebo, with ARIA-E in 12.6% of treated patients;donanemab slowed decline by about 35%, with ARIA-E near 24%. 4 key findings →

Design: narrative review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Neuropathology & Experimental Neurology 2026-07-23

TDP-43 proteinopathies encompass frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), amyotrophic lateral sclerosis (ALS-TDP), and limbic predominant age related TDP-43 encephalopathy neuropathological change (LATE-NC). 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Influence of a Specialized Dementia Ward on the Treatment of Alzheimer’s Disease Patients

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Personalized Medicine 2025-02-25

No statistically significant differences emerged between SDW and GW groups regarding baseline demographics, cognitive function, ADL, or neuropsychiatric symptoms. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Human TDP-43 overexpression in zebrafish motor neurons triggers MND-like phenotypes through gain-of-function mechanism

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Acta Neuropathologica Communications 2025-12-02

Dysregulation of the TAR DNA-binding protein 43 (TDP-43), including intraneuronal cytoplasmic mislocalisation and aggregation is a feature of multiple neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia (FTLD), limbic-predominant age-related TDP-43 encephalopathy (LATE) and alzheimer’s disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Central Insulin-like Growth Factor-1 Treatment Enhances Working and Reference Memory by Reducing Neuroinflammation and Amyloid Beta Deposition in a Rat Model of Sporadic Alzheimer’s Disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmaceuticals 2025-04-04

We found that ICVIGF-1 administration protected working memory demonstrated as (1) reduced latency to reach the platform, and reduced swimming distance in trials 3 (p < 0.05) and 4 (p < 0.01) on days 45 and 90 post-injection and (2) a short-term (up to 45 days post-injection) enhancement of reference memory, manifested by a reduction in swimming distance and latency (p < 0.05). 3 key findings →

Participants: 40 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Frontiers in Aging Neuroscience 2025-07-16

Vascular dementia (VaD) ranks as the second most prevalent subtype of dementia, surpassed only by Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Volatile oil of Acori tatarinowii rhizoma: potential candidate drugs for mitigating dementia

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Frontiers in Pharmacology 2025-04-23

The volatile oil of ATR mitigates dementia through multiple pathways, including reducing abnormal protein aggregation, promoting neurogenesis, inhibiting neuronal apoptosis, regulating neurotransmitters, improving synaptic function, modulating autophagy, countering cellular stress, reducing neuroinflammation, and alleviating vascular risk factors. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’ perspectives

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Therapeutic Advances in Psychopharmacology 2025-10-28

Four GPs and eleven physicians were interviewed, and four major themes emerged: (1) knowledge of best practices of BPSD management, (2) awareness of current challenges in BPSD management, (3) non-involvement, blame shifting and rationalisation: perceived reasons for the current challenges and (4) suggested solutions. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral Small Vessel Disease: Current and Emerging Therapeutic Strategies

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Aging and Disease 2025-01-01

Cerebral small vessel disease (CSVD) is a common disease in older people, characterized by damage to intracranial microvessels, leading to cognitive decline, increased risk of stroke, and dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Early Alzheimer's disease patient care pathway and health system readiness: A framework for integrated care

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-11-05

Alzheimer's disease (AD) is often underdiagnosed, especially at early stages when symptoms are mild, and patients may benefit from new and recently approved anti-amyloid therapies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D

✓ Peer-reviewed alzhub usefulness score 36 out of 100. JAMA Health Forum 2023-02-24

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

From across this tag

10 of the 3,106 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed